Transposición del epiplón como tratamiento neuroquirúrgico de la enfermedad de Alzheimer

Harry S. Goldsmith; Fabián Cremaschi

doi:10.47924/neurotarget2008348

Autores/as

Harry S. Goldsmith Universidad Nacional de Cuyo, Mendoza, Argentina
Fabián Cremaschi Universidad Nacional de Cuyo, Mendoza, Argentina

DOI:

https://doi.org/10.47924/neurotarget2008348

Palabras clave:

enfermedad de Alzheimer, epiplón mayor, omento, tratamiento, cirugía

Resumen

En este breve resumen se presenta la cirugía de transposición del epiplón mayor (epiplón gastrocólico u omento) como una alternativa terapéutica para el tratamiento de la enfermedad de Alzheimer. Se exponen los argumentos por los cuales se propone esta terapia y se concluye que es necesario continuar con la investigación clínica en forma más exhaustiva para confirmar la eficacia de este tratamiento.

Métricas

Cargando métricas ...

Citas

Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003 Aug;60(8):1119-22.

Khachaturian ZS. Diagnosis of Alzheimer's disease: two-decades of progress. J Alzheimers Dis. 2006;9(3 Suppl):409-15.

De la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004 Mar;3(3):184-90. Erratum in: Lancet Neurol. 2004 May;3(5):270.

Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991 Oct;30(4):572-80.

Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996 Oct 4;274(5284):99-102.

Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999 Apr;58(4):376-88.

Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992 Mar;42(3 Pt 1):631-9.

Braak H, Braak E, Bohl J, Reintjes R. Age, neurofibrillary changes, A beta-amyloid and the onset of Alzheimer's disease. Neurosci Lett. 1996 May 31;210(2):87-90.

Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in dif- ferent age categories. Neurobiol Aging. 1997 Jul-Aug;18(4):351-7.

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002 Jul 19;297(5580):353-6. Erratum in: Science 2002 Sep 27;297(5590):2209.

Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA. The production of amyloid beta peptide is a critical requirement for the viability of central neurons. J Neurosci. 2003 Jul 2;23(13):5531-5.

Nakano S, Asada T, Matsuda H, Uno M, Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med. 2001 Oct;42(10):1441-5.

DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002 Feb;51(2):145-55.

de la Torre JC. How do heart disease and stroke become risk factors for Alzheimer's disease? Neurol Res. 2006 Sep;28(6):637-44.

Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology. 1998 Jun;50(6):1563-71.

Meyer JS, Rauch G, Rauch RA, Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol Aging. 2000 Mar-Apr;21(2):161-9.

de la Torre JC. Cerebral hypoperfusion, capillary degeneration, and development of Alzheimer disease. Alzheimer Dis Assoc Disord. 2000;14 Suppl 1:S72-81.

Stieber A, Mourelatos Z, Gonatas NK. In Alzheimer's disease the Golgi apparatus of a population of neurons without neurofibrillary tangles is fragmented and atrophic. Am J Pathol. 1996 Feb;148(2):415-26.

Spilt A, Box FM, van der Geest RJ, Reiber JH, Kunz P, Kamper AM, et al. Reproducibility of total cerebral blood flow measurements using phase contrast magnetic resonance imaging. J Magn Reson Imaging. 2002 Jul;16(1):1-5.

Spilt A, Weverling-Rijnsburger AW, Middelkoop HA, van Der Flier WM, Gussekloo J, de Craen AJ, et al. Late-onset dementia: structural brain damage and total cerebral blood flow. Radiology. 2005 Sep;236(3):990-5.

de la Torre JC, Mussivand T. Can disturbed brain microcirculation cause Alzheimer's disease? Neurol Res. 1993 Jun;15(3):146-53.

Roher AE, Kokjohn TA, Beach TG. An association with great implications: vascular pathology and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):73-5.

Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, Hofman A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol. 2005 Jun;57(6):789-94.

Fischer VW, Siddiqi A, Yusufaly Y. Altered angioarchitecture in selected areas of brains with Alzheimer's disease. Acta Neuropathol. 1990 Apr;79(6):672-9.

De la Torre JC. Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurol Res. 2004 Jul;26(5):517-24.

De la Torre JC. Critically attained threshold of cerebral hypoperfusion: can it cause Alzheimer's disease? Ann NY Acad Sci. 2000 Apr;903:424-36.

Roher AE, Garami Z, Alexandrov AV, Kokjohn TA, Esh CL, Kalback WM, et al. Interaction of cardiovascular disease and neurodegeneration: transcranial Doppler ultrasonography and Alzheimer's disease. Neurol Res. 2006 Sep;28(6):672-8.

Maalikjy Akkawi N, Borroni B, Agosti C, Magoni M, Broli M, Pezzini A, et al. Volume cerebral blood flow reduction in pre-clinical stage of Alzheimer disease: evidence from an ultrasonographic study. J Neurol. 2005 May;252(5):559-63.

Miklossy J. Cerebral hypoperfusion induces cortical watershed microinfarcts which may further aggravate cognitive decline in Alzheimer's disease. Neurol Res. 2003 Sep;25(6):605-10.

Goldsmith HS, Bacciu P, Cossu M, Pau A, Rodriguez G, Rosadini G, et al. Regional cerebral blood flow after omental transposition to the ischaemic brain in man. A five year follow-up study. Acta Neurochir (Wien). 1990;106(3-4):145-52.

Goldsmith HS. Role of the omentum in the treatment of Alzheimer's disease. Neurol Res. 2001 Sep;23(6):555-64.

Goldsmith HS. Treatment of Alzheimer's disease by transposition of the omentum. Ann NY Acad Sci. 2002 Nov;977:454-67.

Goldsmith HS, Wu W, Zhong J, Edgar M. Omental transposition to the brain as a surgical method for treating Alzheimer's disease. Neurol Res. 2003 Sep;25(6):625-34.

Goldsmith HS. Omental transposition to the brain and spinal cord. Surg Rounds. 1986; 9: 22-33.

Goldsmith HS, Chen WF, Duckett SW. Brain vascularization by intact omentum. Arch Surg. 1973 May;106(5):695-8.

Pau A, Sehrobundt Viale E, Turtas S. Effect of omental transposition on to the brain on the cortical content of norepinephrine, dopamine, 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in experimental cerebral ischaemia. Acta Neurochir (Wien). 1982;66(3-4):159-64.

Goldsmith HS, McIntosh T, Vezina RM, Colton T. Vasoactive neurochemicals identified in omentum: a preliminary report. Br J Neurosurg. 1987;1(3):359-64.

Siek G, Maquis JK, Goldsmith HS. Experimental studies of omentum-derived neurotrophic factors. In: Goldsmith HS, editor. The omentum: Research and Clinical Applications. New York: Springer-Verlag; 1990. p. 109-16.

Goldsmith HS, Griffith AL, Kupferman A, Catsimpoolas N. Lipid angiogenic factor from omentum. JAMA. 1984 Oct 19;252(15):2034-6.

Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, Rosengart TK. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res. 1997 Feb 1;67(2):147-54.

Dujovny M, Ding YH, Ding Y, Agner C, Perez-Arjona E. Current concepts on the expression of neurotrophins in the greater omentum. Neurol Res. 2004 Mar;26(2):226-9.

García-Gómez I, Goldsmith HS, Angulo J, Prados A, López-Hervás P, Cuevas B, et al. Angiogenic capacity of human omental stem cells. Neurol Res. 2005 Dec;27(8):807-11.

Goldsmith HS, editor. The Omentum: Application to Brain and Spinal Cord. Wilton, Connecticut: Forefront Publishing; 2000.

Shankle WR, Hara J, Bjornsen L, Gade GF, Leport PC, Ali MB, et al. Omentum transposition surgery for patients with Alzheimer's disease: a case series. Neurol Res. 2008 Apr;30(3):313-25.

Clifton GL, Donovan WH, Dimitrijevic MM, Allen SJ, Ku A, Potts JR 3rd, Moody FG, Boake C, Sherwood AM, Edwards JV. Omental transposition in chronic spinal cord injury. Spinal Cord. 1996 Apr;34(4):193-203.

Goldsmith HS. Omental transposition in chronic spinal cord injury. Spinal Cord. 1997 Mar;35(3):189-90.